Investment Analysts’ Recent Ratings Updates for Cencora (COR)

Cencora (NYSE: COR) recently received a number of ratings updates from brokerages and research firms:

• 5/22/2026 – Cencora was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 5/11/2026 – Cencora had its price target lowered by Wells Fargo & Company from $429.00 to $331.00. They now have an “overweight” rating on the stock.
• 5/8/2026 – Cencora was given a new $342.00 price target by Morgan Stanley.
• 5/7/2026 – Cencora had its price target raised by UBS Group AG from $410.00 to $412.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Cencora had its price target lowered by Citigroup Inc. from $405.00 to $355.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Cencora had its price target lowered by Robert W. Baird from $420.00 to $339.00. They now have an “outperform” rating on the stock.
• 5/4/2026 – Cencora had its “buy (b)” rating reaffirmed by Weiss Ratings.
• 4/28/2026 – Cencora is now covered by William Blair. They set a “market perform” rating on the stock.
• 4/8/2026 – Cencora was given a new $360.00 price target by Evercore Inc.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 1st. Stockholders of record on Friday, May 15th will be given a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.